CYP Suppression in Human Hepatocytes by Monomethyl Auristatin E, the Payload in Brentuximab Vedotin (Adcetris®), is Associated with Microtubule Disruption.

about

CYP Suppression in Human Hepatocytes by Monomethyl Auristatin E, the Payload in Brentuximab Vedotin (Adcetris®), is Associated with Microtubule Disruption.

Item

http://www.wikidata.org/entity/Q49629406

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

CYP Suppression in Human Hepat ...... d with Microtubule Disruption.

@en

CYP Suppression in Human Hepat ...... d with Microtubule Disruption.

@nl

type

Item

label

CYP Suppression in Human Hepat ...... d with Microtubule Disruption.

@en

CYP Suppression in Human Hepat ...... d with Microtubule Disruption.

@nl

prefLabel

CYP Suppression in Human Hepat ...... d with Microtubule Disruption.

@en

CYP Suppression in Human Hepat ...... d with Microtubule Disruption.

@nl

P1476

CYP Suppression in Human Hepat ...... d with Microtubule Disruption.

@en

P2093

Bingli Ma

http://www.w3.org/2001/XMLSchema#string

Cindy Q Xia

http://www.w3.org/2001/XMLSchema#string

Francis S Wolenski

http://www.w3.org/2001/XMLSchema#string

Suresh K Balani

http://www.w3.org/2001/XMLSchema#string

Tae H Han

http://www.w3.org/2001/XMLSchema#string

Wen C Shyu

http://www.w3.org/2001/XMLSchema#string

P2860

NIH Image to ImageJ: 25 years of image analysis

Colchicine down-regulates cytochrome P450 2B6, 2C8, 2C9, and 3A4 in human hepatocytes by affecting their glucocorticoid receptor-mediated regulation.

Role of microtubules network in CYP genes expression.

A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia.

CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies

Antibodies to watch in 2017

Brentuximab vedotin

Considerations from the IQ Induction Working Group in Response to Drug-Drug Interaction Guidances from Regulatory Agencies: Focus on Down-regulation, CYP2C Induction and CYP2B6 Positive Control.

Antibody drug conjugates: lessons from 20 years of clinical experience.

P2888

s13318-017-0455-5

P31

scholarly article

P356

10.1007/S13318-017-0455-5

http://www.w3.org/2001/XMLSchema#string

P577

2017-12-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1099746334

http://www.w3.org/2001/XMLSchema#string

P698

29264831

http://www.w3.org/2001/XMLSchema#string